ReviewVirchows Archiv : an international journal of pathology2026
Novel concepts of cell-of origin in neuroendocrine neoplasms.
Review in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinically actionable molecular alterations in Rb-retained small cell lung carcinoma variants.Virchows Archiv : an international journal of pathology · 2026Article
- Vulvar small cell neuroendocrine carcinoma arising from differentiated vulvar intraepithelial neoplasia: evidence of a clonal relationship by mutation analysis.Virchows Archiv : an international journal of pathology · 2026Article
- Comprehensive Overview of Gastric Cancer Immunohistochemistry: Key Biomarkers, Advanced Detection Methods, and Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Hedgehog signaling drives glial cell plasticity and oncogenic reprogramming in gastroenteropancreatic neuroendocrine neoplasms.Molecular cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors. The rarity of the disease, together with the lack of mutations in the classical tumor suppressor genes and the paucity of models, has impaired our understanding of the mechanisms of progression and the cell of origin of these tumors. Due to their higher frequency, this review focuses on Gastro-Entero-Pancreatic (GEP) and Lung NENs. While recent molecular profiling has shed light on the possible cell of origin of GEP- and lung NENs, many questions remain unanswered and further studies using proper in vitro and in vivo models are needed, combined with the latest technologies such as single-cell and spatial sequencing and deep-learning for digital pathology. Genomic and epigenomic evidence suggests that pancreatic NENs originate from adult pancreatic cells rather than common progenitor cells; however, ultimate proof in vitro or in vivo is still lacking. Similarly, emerging molecular evidence suggests that lung NENs may have very diverse origins, encompassing most lung cell types, but much work is still needed to pinpoint their cell of origin. Further, tumors with mixed endocrine and non-endocrine composition suggest the possibility of trans-differentiation and acquisition of neuroendocrine features in different cell types. This review aims to summarize emerging insights on this topic, highlight future directions for identifying the cell of origin of NENs in these organs and explore how this knowledge may ultimately translate into clinical advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.